Suboptimal response to imatinib therapy
| . | Percentage of patients failing to achieve reductions . | ||
|---|---|---|---|
| 1-log reduction in BCR-ABL by 6 months . | 2-log reduction in BCR-ABL by 12 months . | 3-log reduction in BCR-ABL by 18 months . | |
| Patients receiving 600 mg or more ADD | |||
| High OCT-1 activity (n = 15) | 7 | 13 | 20 |
| Low OCT-1 activity (n = 18) | 0 | 0 | 44 |
| P value | .669 | .560 | .133 |
| Patients receiving less than 600 mg | |||
| High OCT-1 activity (n = 12) | 0 | 8 | 17 |
| Low OCT-1 activity (n = 11) | 27 | 45 | 82 |
| P value | .005 | .021 | .022 |
| . | Percentage of patients failing to achieve reductions . | ||
|---|---|---|---|
| 1-log reduction in BCR-ABL by 6 months . | 2-log reduction in BCR-ABL by 12 months . | 3-log reduction in BCR-ABL by 18 months . | |
| Patients receiving 600 mg or more ADD | |||
| High OCT-1 activity (n = 15) | 7 | 13 | 20 |
| Low OCT-1 activity (n = 18) | 0 | 0 | 44 |
| P value | .669 | .560 | .133 |
| Patients receiving less than 600 mg | |||
| High OCT-1 activity (n = 12) | 0 | 8 | 17 |
| Low OCT-1 activity (n = 11) | 27 | 45 | 82 |
| P value | .005 | .021 | .022 |
Data are percentages except for P values.